Medivir: An all-oral combination phase II study of Simeprevir and Samatasvir for the treatment of hepatitis C virus infection initiated Phase II HELIX-1 trial is first hepatitis C clinical study to commence through collaboration agreement between Janssen Pharmaceuticals Inc.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130530005723&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130530005723&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment